Daniel Starks Purchases 10,000 Shares of Abbott Laboratories (NYSE:ABT) Stock

Abbott Laboratories (NYSE:ABT) Director Daniel Starks bought 10,000 shares of the stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $91.52 on Thursday. The firm has a 50-day moving average price of $104.76 and a 200-day moving average price of $116.38. The firm has a market capitalization of $159.40 billion, a PE ratio of 25.64, a price-to-earnings-growth ratio of 1.55 and a beta of 0.79. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12-month low of $90.72 and a 12-month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter last year, the business posted $1.09 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Analyst Ratings Changes

ABT has been the subject of a number of research analyst reports. Argus decreased their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Citigroup decreased their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Wells Fargo & Company decreased their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a report on Wednesday, April 22nd. Finally, Barclays cut their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $119.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Seelaus Asset Management LLC grew its position in shares of Abbott Laboratories by 2.0% in the 1st quarter. Seelaus Asset Management LLC now owns 6,273 shares of the healthcare product maker’s stock worth $644,000 after buying an additional 125 shares during the last quarter. IAG Wealth Partners LLC grew its position in shares of Abbott Laboratories by 43.1% in the 1st quarter. IAG Wealth Partners LLC now owns 531 shares of the healthcare product maker’s stock worth $54,000 after buying an additional 160 shares during the last quarter. Staley Capital Advisers Inc. grew its position in shares of Abbott Laboratories by 11.8% in the 1st quarter. Staley Capital Advisers Inc. now owns 7,457 shares of the healthcare product maker’s stock worth $766,000 after buying an additional 788 shares during the last quarter. Nichols & Pratt Advisers LLP MA grew its position in shares of Abbott Laboratories by 23.4% in the 1st quarter. Nichols & Pratt Advisers LLP MA now owns 41,870 shares of the healthcare product maker’s stock worth $4,299,000 after buying an additional 7,950 shares during the last quarter. Finally, Sageworth Trust Co grew its position in Abbott Laboratories by 36.7% during the 1st quarter. Sageworth Trust Co now owns 27,828 shares of the healthcare product maker’s stock worth $2,857,000 after purchasing an additional 7,470 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Insiders buying shares — Director Daniel Starks purchased 10,000 shares, a vote-of-confidence signal that can stabilize sentiment for long-term holders. SEC Form 4 – Daniel Starks purchase
• Positive Sentiment: CFO Philip Boudreau also bought shares (~2,200 at ~$91.50), which investors often read as management putting capital to work. CFO Philip Boudreau Buys 2,200 Shares
• Positive Sentiment: Regulatory win — Abbott received FDA clearance and a CE Mark for its Ultreon™ 3.0 AI coronary imaging software, strengthening the medtech growth story for high‑margin cardiovascular devices. Ultreon 3.0 FDA clearance and CE Mark
• Neutral Sentiment: Citi reaffirmed a buy rating — institutional analyst support may limit further downside but hasn’t fully offset concerns. Citi Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Neutral Sentiment: Active manager repositioning — Polen Focus Growth exited ABT in Q1, reflecting some portfolio-level rotation rather than company‑specific change. That can add short‑term selling pressure but is not a direct operational signal. Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1
• Negative Sentiment: Guidance trimmed / acquisition dilution — Abbott narrowed FY26 EPS to $5.38–$5.58 and cited roughly $0.20 of dilution from the $21B Exact Sciences deal, a primary driver of the selloff and recent 52‑week lows. Q1 Earnings and Exact Sciences Acquisition Fallout
• Negative Sentiment: Analyst target cuts & device/diabetes softness — several firms trimmed price targets and highlighted near‑term weakness in diabetes and some medtech end markets, increasing downside risk until revenue mix normalizes. Analyst reaction and market commentary

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.